EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,901 JPY | +1.32% |
|
-2.32% | -16.32% |
| Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
| Apr. 01 | BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
5,824
JPY
Average target price
8,193
JPY
Spread / Average Target
+40.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.32% | 10.8B | |
| +27.97% | 672B | |
| +23.59% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.36% | 211B | |
| -0.64% | 203B | |
| -10.22% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 4523 Stock
- News Eisai Co., Ltd.
- US FDA To Review Eisai JV's Biologics License Submission For Early Alzheimer's Therapy
